Probucol for non-proliferative diabetic retinopathy with hyperlipidemia

( views:1242, downloads:0 )
CHEN Zhong-ping()
ZHANG Ru-ming(Department of Ophthalmology, The First Affiliated Hospital to South China University,421001 Hengyang, China)
Journal Title:
Chinese Journal of Ocular Fundus Diseases
Volume 28, Issue 05, 2012
Key Word:
Diabetic retinopathy/drug therapy; Hyperlipidemias/drug therapy; Probucol/therapeutic use

Abstract: Objective To observe the effectiveness of probucol for non-proliferative diabetic retinopathy (NPDR) with hyperlipidemia.Methods Fifty-two patients (104 eyes) of NPDR with hyperlipidemia were enrolled in this study.The patients were randomly divided into treatment group and control group,26 patients (52 eyes) in each group.Both groups received diet and exercise guidance,oral hypoglycemic agents and (or) intensive insulin therapy.After blood sugar and blood pressure were controlled,the treatment group received probucol 0.5 g,two times per day; and the control group received atorvastatin of 10 mg,one time per day.The total course was 12 months.Before and after one,three,six and 12 months,all patients underwent vision,ophthalmoscope,fundus fluorescein angiography,blood and urine tested.Variations of visual acuity,fundus condition,macular edema,triglyceride (TG),total cholesterol (TC),low-density lipoprotein cholesterol (LDLC),high-density lipoprotein cholesterol (HDLC) and 8-0HdG were observed before and after treatment.Results The total effective rate of visual prognosis were 44.23% and 40.38% in the treatment group and the control group,the difference had no statistical significacy (Z=-0.335,P>0.05).Retinal hemorrhages and microaneurysms alleviated after treatment in both groups.The total efficiency of fundus prognosis was 65.38% in the treatment group and 36.54% in the control group,and the difference was statistically significant (Z=-2.973,P<0.05).Macular edema was in six and five eyes in the treatment group and the control group respectively,which were lower than before treatment,the difference was statisticaly significant (x2=4.833,4.300; P<0.05).Between the two groups,the difference was not statistically significant (x2 =0.102,P> 0.05).Twelve months after treatment,TG,TC and LDLC were decreased in the treatment group (t=15.653,7.634,14.871) and control group (t=13.275,7.415,13.632),and the difference was statistically significant (P<0.05).HDLC showed no significant difference than before in the two groups (t=0.584,0.275; P>0.05).TG,TC,LDLC and HDLC showed no difference between the two groups (t=1.857,0.133,1.671,0.875; P>0.05).8-0HdG decreased gradually during the one,three,six and 12 months in the treatment group (t=7.352,15.581,27.324,28.143) and control group (t =6.877,8.672,14.671,14.855) after treatment,and the difference was statistically significant (P<0.05).In the first month aftertreatment,8 0HdG showed no difference between the two groups (t=0.513,P>0.05).In the 3,6,and 12 months after treatment,the 8 0HdG was lower in the treatment group than that in the control group,and the difference was statistically significant (t =3.434,5.917,5.226; P<0.05).Conclusion In the treatment of NPDR with hyperlipidemia,probucol can reduce blood lipid,stable visual function and relieve macular edema.

  • [1]Brownlee M.Biochemistry and molecular cell biology of diabetic complications.Nature,2001,414:813-820.
  • [2]Dong QY,Cui Y,Chen L,et al.Urinary 8-hydroxydeoxyguanosine levels in diabetic retinopathy patients.Eur J Ophthalmol,2008,18:94-98.
  • [3]Abbate M,Cravedi P,Iliev I,et al.Prevention and treatment of diabetic retinopathy:evidence from clinical trials and perspectives.Curr Diabetes Rev,2011,7:190-200.
  • [4]Agardh E,Hultberg B,Agardh C.Effects of inhibition of glycation and oxidative stress on the development of cataract and retinal vessel abnormalities in diabetic rats.Curr Eye Res,2000,21:543-549.
  • [5]陈忠平,张入铭,蒋苏平,等.普罗布考治疗非增殖型糖尿病视网膜病变临床观察.中国动脉硬化杂志,2010,18:552-555.
  • [6]World Health Organization.Definition,diagnosis and classification of diabetes mellitus and its complications Part 1:diagnosis and classification of diabetes mellitus.Report of a WHO Consultation.Geneva:WHO,1999:20-16.
  • [7]中华医学会眼科学分会眼底病学组.糖尿病视网膜病变分期标准.眼底病,1998,1:42.
  • [8]中国成人血脂异常防治指南制订联合委员会.中国成人血脂异常防治指南.中华心血管病杂志,2007,35:390-419.
  • [9]张美霞,杨兰芬,罗成仁,等.糖尿病视网膜病变黄斑水肿的临床分析.中华眼底病杂志,2003,19:83-86.
  • [10]段俊国,廖品正,吴烈,等.中药复方芪明颗粒治疗糖尿病视网膜病变双盲双模拟随机对照多中心临床研究.成都中医药大学学报,2006,29:1-5.
  • [11]李晨钟,张素华,汪湘琳,等.糖尿病视网膜病变与脂质代谢紊乱的关系.中华眼底病杂志,1998,14:21-23.
  • [12]Rema M,Srivastava BK,Anitha B,et al.Association of serum lipids with diabetic retinopathy in urban South Indians——the Chennai Urban Rural Epidemiology Study (CURES) Eye Study-2.Diabet Med,2006,23:1029-1036.
  • [13]Golubovic-Arsovska M.Association of dyslipidaemia with macular oedema and hard exudates in diabetic maculopathy.Prilozi,2007,28:149-160.
  • [14]Panagiotoglou TD,Ganotakis ES,Kymionis GD,et al.Atorvastatin for diabetic macular edema in patients with diabetes mellitus and elevated serum cholesterol Ophthalmic Surg Lasers Imaging,2010,41:316-322.
  • [15]Gupta A,Gupta V,Thapar S,et al.Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema.AmJ Ophthalmol.2004,137:675-682.
  • [16]Quagliaro L,Piconi L,Assaloni R,et al.Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells:the role of protein kinase C and NAD(P)H-oxidase activation.Diabetes,2003,52:2795-2804.
  • [17]Suzuki S,Hinokio Y,Komatu K,et al.Oxidative damage to mitochondrial DNA and its relationship to diabetic complications.Diabetes Res Clin Pract,1999,45:161-168.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615